Scott Struthers, Crinetics CEO

FDA re­jects Cri­net­ic­s' cur­rent PhII de­sign for hy­per­in­sulin­ism drug

The FDA has put a stop to Cri­net­ics’ plans for a Phase II tri­al on its con­gen­i­tal hy­per­in­sulin­ism drug, the com­pa­ny an­nounced Mon­day morn­ing. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.